abstract | Rheumatoid arthritis (RA) is a chronic, debilitating autoimmune disease that results in inflammation and structural destruction of the joints. A hallmark of RA pathogenesis is an imbalance of the osteoblast-osteoclast axis driven by inflammatory processes, resulting in elevated bone resorption by osteoclasts. Current therapies used to treat this disease have focused on inhibition of synovitis, but such treatments do not adequately repair damaged bone. A key pathway of osteoclast formation involves the receptor activator of nuclear factor κB ligand (RANKL) pathway acting on myeloid progenitor cells. The Wnt pathway has been shown to be important for the differentiation of osteoblasts from mesenchymal lineage precursors, and endogenous Wnt inhibitors, such as Dickkopf1 and sclerostin, might have important roles in osteoclast dysregulation in RA. Inhibition of the RANKL pathway, or blockade of Dickkopf1 and sclerostin, might serve to restore the osteoblast-osteoclast balance and repair bone erosion in RA joints. Such treatments, in combination with anti-inflammatory therapies, could stabilize and repair damaged joints and have the potential to be valuable additions to the armory of RA treatments.
Background in addition to inflammation of the synovium, a major clinical manifestation of rheumatoid arthritis (ra) is the progressive destruction of bone and cartilage struc tures in the joints of patients, leading to radiographically defined features, such as bone erosion and joint space narrowing. typical pathogenic processes in the syno vium of patients with ra include a thickened hyper plastic synovial layer, neoangiogenesis, and ongoing migration of macrophages and autoreactive lymphocytes into the joints resulting from the action of chemokines and pro inflammatory cytokines.
1 these inflammatory processes have been intensively studied, and are known to activate bone and cartilage destruction via the action of tumor necrosis factor (tnF) and receptor activator of nuclear factor κB ligand (ranKl; also known as tnF ligand superfamily, member 11) mediated signaling, amongst other signaling pathways, on bone resorp tive osteoclast cell formation and activation of synovial fibroblasts.
2 therapies used in the clinic for the success ful treatment of ra target various aspects of these inflammatory pathways (for example, corticosteroids, methotrexate, antitnF agents, interleukin [il] 1β and il6 pathway blockade, Bcell depletion via targeting of CD20, and blockade of lymphocyte costimulation via cytotoxic tlymphocyte antigen 4 1,3-9 ). Bisphosphonates (pyrophosphate analogues that target osteoclasts), which are currently considered the st andard of care for reduc ing bone loss in post menopausal osteoporosis, are also used to prevent bone destruction in ra, whether this is caused by inflammatory processes or following expo sure to commonly used antiinflammatory treatments such as glucocorticoids. although anecdotal reports of bisphosphonate use in patients with ra are widespread, there is a dearth of appropriately designed clinical trials that specifically investigate the effects of these drugs in ra. 10, 11 thus, although most of these therapies have been shown to slow progressive joint damage as determined by radiography, 5,9,12,13 not all patients respond robustly to these therapies with respect to bone erosion. Hence, in addition to targeting syno vitis, it is highly desirable to find mechanisms to stop and ultimately reverse bone erosion in ra.
the normal mechanism by which bones are formed and resorbed is mediated via the interaction between two cell lineages: boneforming osteoblasts and bone resorbing osteoclasts (Figure 1 ). osteoblasts differen tiate from mesenchymal stem cells under the control of key signals, such as parathyroid hormone, the canonical wnt-βcatenin pathway and the bone morphogenetic protein (BmP) pathway.
14,15 these signaling pathways produce key bone matrix products that are subsequently mineral ized. osteoclasts differentiate from myeloid lineage precursors under the control of the key pathways involving colony stimulating factor 1 and the ranKlranK axis, which act at early and terminal differen tiation stages, respectively.
2,16,17 these cells degrade bone via expression of effector molecules such as cathepsins, matrix metalloproteinases, and local production of hydrogen ions. thus, these two types of effector cells, derived from in dependent precursor line ages and with opposing functions, act in concert to maintain normal bone metabolism. Cross regula tion of these cell types can occur; for example, the ranKl decoy receptor osteo protegerin (oPG) is expressed by osteoblasts, induced by wnt signaling, 18 and acts to repress the osteoclast 2, 19, 20 in the case of ra, the osteoblast-osteoclast axis is severely disrupted owing to ongoing inflammatory processes resulting in enhanced osteoclast function. 21, 22 Key macrophagederived and tcellderived pro inflammatory cytokines, such as tnF, il1β, il6 and il17, act in a pleiotropic network to induce expression of ranKl by synovial fibroblasts, osteoblasts and bone marrow stromal cells, leading to enhanced osteoclast differen tiation. [23] [24] [25] [26] [27] in addition, ranKl is expressed by activated CD4 + t cells infiltrating the synovium, provid ing other cellular sources of this osteoclastgenerating protein under inflammatory conditions. 23,28,29 tnF also acts directly on osteoclast formation via signaling through tnFrsF1a (tumor necrosis factor receptor superfamily, member 1a), and il1β can upregulate the expression of ranK on osteoclast progenitors. 30, 31 increased signaling through ranK on differentiating osteoclasts results in recruitment of tnF receptor associated factor 6 and subse quent activation of the transcription factor nFatc1, which is a master regula tor of osteoclastogenesis. 32, 33 this inflammationdriven activation of the ranKl-ranK pathway increases osteoclast levels in the joints, and thus drives bone destruction in ra.
Perturbations to the osteoblast axis have also been implicated in ra pathogenesis because of the lack of bone repair activities after formation of erosions in this disease. indeed, a mouse arthritis study showed that inflammation within arthritic bone resulted in a decrease in the numbers of mature cells of the osteoblast lineage and concomitant bone formation. 34 the BmP and canonical wnt-βcatenin pathways have been impli cated in osteoblast function and bone formation. [35] [36] [37] BmPs signal through heteromeric BmP type i and type ii serine-threonine kinase receptor complexes, and activate downstream osteoblast transcriptional pathways via phosphorylation of receptorregulated smaD com plexes. 15, 37 wnt proteins bind to the membrane recep tors lowdensity lipoprotein receptorrelated protein (lrP)5 and lrP6, together with the coreceptor Frizzled ( Figure 2 ). Formation of this transmembrane complex results in activation of Dishevelled and initiates down stream intracellular signaling. βCatenin, via changes in its phosphorylation status, is released from a destruc tion complex comprising the proteins axin, glycogen synthase kinase 3 and adenomatosis polyposis coli, and accumulates in the cell. translocation of βcatenin to the nucleus induces the expression of target genes, including alkaline phosphatase and connective tissue growth factor family genes, via the βcatenin-t cell factor/lymphoid enhancer binding factor 1 complex and drives differentiation of me senchymal cells into osteoblasts. Under the inflammatory conditions of RA, activity of infiltrating macrophages and CD4 + T cells results in expression of proinflammatory cytokines, such as TNF, that drive osteoclast formation via induction of RANKL in the synovium. In addition, RANKL is expressed on synovial fibroblasts and infiltrating T cells. The resulting osteoclasts, and associated local production of H + ions and cathepsin K, lead to increased bone resorption and joint destruction. Abbreviations: BMP, bone morphogenetic protein; FLS, fibroblast-like synoviocyte; IL, interleukin; MMPs, matrix metalloproteinases; NO, nitric oxide; RA, rheumatoid arthritis; RANKL, receptor activator of nuclear factor κB ligand; TNF, tumor necrosis factor. r e V I e W s importantly, there are several endogenous inhibitors of the canonical wnt pathway that regulate osteoblast function. Dickkopf1 (DKK1), a member of a family of cysteinerich proteins, functions as an inhibitor of wnt signaling via competitive binding to the lrP5/ lrP6 receptor complex, and by recruiting kringle containing transmembrane protein 1, a negative coreceptor.
41,42 levels of DKK1 are increased in both experimental arthritis and in human ra synovial tissue and serum, and expression of DKK1 is induced by tnF signaling. 43 another protein of interest, sclerostin, is a secreted glycoprotein of the evolutionarily conserved Dan (differen tial screeningselected gene aberrant in the neuroblastoma) family of proteins containing a cysteineknot motif, and has been implicated as an inhibitor of both the wnt and BmP pathways driving osteoblast formation. 44, 45 unlike DKK1 and other wnt antagonists, sclerostin is unique in that it is produced by osteocytes and so is an endo genous mediator in the bone formation-destruction axis. 46 sclerostin binds to BmPs as well as to lrP5/lrP6, thus antagonizing BmP and wnt signaling and, hence, osteoblast formation. [47] [48] [49] inherited genetic mutation of the SOST gene (which encodes sclerostin in humans) results in sclerosteosis, a progressive bone dysplasia disorder. 50 Given the important roles of the ranKl-ranK pathway in bone resorption, and the wnt and BmP pathways in bone formation and repair, strategies target ing both ranK signaling as well as targeting antago nists of the wnt and BmP pathways, such as DKK1 and sclero stin, might provide avenues both to inhibit bone destruction and potentially to repair erosions in ra.
Preclinical data
inhibition of ranK signaling has been shown to be beneficial in several animal models of arthritis. in a tnFinduced mouse model of arthritis, inflamma tion and bone erosion were blocked more effectively by simultaneous treatment with antitnF agents and the ranKl decoy receptor oPG than with antitnF alone; 51 oPG treatment alone slowed joint destruction, but did not affect inflammation. 52, 53 in a rat adjuvant induced arthritis model, treatment with oPG at the time of disease onset resulted in decreased bone erosion, but did not affect inflammatory progression. 28 using the K/Bxn mouse model of serumtransferred arthritis, ranKldeficient mice were protected against bone loss but not inflammation. 54 similarly, in a rat adjuvant induced arthritis model, treatment with oPG resulted in decreased loss of bone mineral density, but did not affect inflammation. 55 Blockade of intracellular signaling path ways downstream of ranK also prevented bone loss or destruction in inflammationinduced and ovariectomy induced bone loss mouse models. 56 inhibition of ranK signaling is, therefore, beneficial for protection against bone damage in multiple animal arthritis models, but has little benefit in inhibiting the inflammatory axis of the disease. antibodymediated blockade of DKK1 resulted in a decrease in bone erosion but did not affect inflam matory signs of disease in the tnFinduced mouse arthritis model and the collageninduced mouse arthritis model. 43 interestingly, blockade of DKK1 also resulted in new bone production due to formation of osteophytes, in dicating elevated differentiation of osteoblasts. in addi tion, blockade of DKK1 decreased osteoclast numbers in the joints; this finding was ascribed to upregula tion of oPG levels via wnt signaling. Furthermore, targeted deletion of one allele of DKK1 in mice was shown to be sufficient to result in increased osteoblast number and bone forma tion. 57 importantly, these data suggest that boosting osteoblast function through blockade of wnt antagonists can overcome and repair ongoing bone destruction in arthritis independently of inflammation.
targeted deletion of sclerostin in mice results in increased bone volume, bone mineral density and bone strength compared with wild type controls. 58 sclerostin deficient animals had increased osteoblast activity as well f o C u s o n t h e f u t u r e o f t h e r a P y f o r r a as increased serum levels of osteo calcin, an osteoblast marker, but the osteoclast axis was unaffected. a further study using the ovariectomized rat model of post menopausal osteoporosis showed that adminis tration of an antibody against sclerostin resulted in increased bone formation on multiple bone surfaces after 5 weeks of treatment. 59 in addition, antibody mediated bloc kade of sclerostin in a mouse model of chronic colitis was shown to halt inflammationinduced bone loss. 60 these data support the notion that sclero stin, like DKK1, is an important antagonist of osteoblast formation and that inhibition of this pathway has potential benefit for bo osting bone repair.
Clinical data a monoclonal antibody against ranKl, denosumab, has been developed and tested in the clinic. the development of this antibody has focused on post menopausal osteoporosis, and positive outcome data have been reported. 61 a 12month placebocontrolled phase ii study of this antibody was also conducted in ra patients. 62 this study showed a dose-response effect of denosumab on decreases in mridetermined erosion scores compared with placebo as early as 6 months after treatment, and both of the tested doses of deno sumab decreased radiographydetermined sharp erosion scores after 12 months of treatment. in addi tion, ranKl blockade resulted in rapid and sustained suppression of the systemic markers of bone turnover Ctelopeptide of type i collagen and npropeptide of type i collagen, but only transiently decreased the carti lage marker Ctelopeptide of type ii collagen after 3 months of treatment. Consistent with preclinical observations, denosumab treatment had no effect on measures of ra disease activity, such as components of the american College of rheumatology response cri teria, Health assessment Questionnaire scores or the Das28 (disease activity score 28joint count), compared with placebo, suggesting that it does not substantially affect the inflammatory component of ra.
Future clinical development
as discussed above, there is considerable evidence that inhibition of osteoclast function via blockade of ranKl, and enhancement of osteoblast function via blockade of the wnt/BmP antagonists DKK1 and sclerostin, might help reduce ongoing bone erosion and repair existing joint damage; however, blockade of these pathways is not likely to affect inflammationdependent signs and symp toms of ra, such as joint swelling and tenderness. these differing mechanisms of action have two implica tions for the clinical development of these potential therapies: first, they will likely require coadministration with well established antiinflammatory therapies, such as metho trexate or antitnF agents; second, appropriate end points, such as radiographic and mridefined erosion scores rather than signs and symptoms end points such as change in american College of rheumatology and Das28 scores, must be u tilized during clinical trials to determine the contribution of these therapies to meaning ful clinical outcomes.
the patient population most likely to benefit from such a therapeutic intervention would also have to be carefully considered. For example, there have been reports of ra patients who are considered to be in a state of disease remission, but yet have progressive radiographic joint destruction. 63 such patients pre sumably have an inflammationindependent, bone destructive disease manifestation, and might benefit more from alteration of the osteoclast-osteoblast balance rather than from other therapies that target only the in flammatory cascade.
we need to optimize the therapeutic window for these treatments to avoid adverse effects, such as pushing bone resorption or bone formation too far in the oppo site direction, resulting in inappropriate bone formation characteristic of anabolic bone disorders (for example, osteoarthritis and ankylosing spondylitis) and neo plastic transformation resulting from excessive activa tion of the wnt or BmP pathways, or both.
64,65 the risk of onco genesis caused by longterm activation of the wnt pathway through antagonism of DKK1 or sclerostin must also be considered. 66 Outlook the progress made over the past few years in defin ing the molecular basis of controlling osteoblast and osteoclast differentiation has presented new opportu nities to target bone disorders in the clinic. as bone destruction and concomitant lack of new bone forma tion is a major clinical manifestation of ra, thera peutic intervention to reverse these pathogenic processes should have consider able clinical benefit for patients with this disease. such therapies will likely need to be administered in combina tion with wellestablished and costeffective anti inflammatory therapies such as methotrexate, and might benefit patients who have clear evidence of bone destruction even though their inflam matory disease is well controlled. as, at present, joint destruction in ra is irreversible and highly debilitating, this alternative therapeutic intervention, if successful, would be a major addition to existing antiinflammatory treatment paradigms for this disease.
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